Search Existing Participant Requests

The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.


Search Terms:


Investigator: Marie McNeely

Project Title: Development of a clinical tool to predict fall risk in Alzheimer disease

Date: December 21, 2021 at 5:28 pm

Request ID: S1602

Aim 1: Identify predictors of falls in a large sample of individuals with Alzheimer disease.

Aim 2: Develop a new, simple clinical fall prediction tool that would be useful in routine care of individuals with Alzheimer disease.

Aim 3:

Aim 4:


Investigator: Susan L Stark

Project Title: Participant Retention Study

Date: December 21, 2021 at 5:28 pm

Request ID: S1603

Aim 1: Characterize the barriers and facilitators to longitudinal research in the KADRC

Aim 2: Characterize the reason for missing data in the KADRC longitudinal dataset

Aim 3:

Aim 4:


Investigator: John C. Morris

Project Title: Vascular Contributions to Dementia and Genetic Risk Factors for Alzheimer�s Disease

Date: December 21, 2021 at 5:28 pm

Request ID: S1701

Aim 1: To show that loss of blood-brain barrier (BBB) integrity links vascular injury to neuronal injury in AD

Aim 2: Examine temporal relationship between BBB permeability, cerebral blood flow (CBF) and white matter lesions

Aim 3:

Aim 4:


Investigator: Jason Hassenstab

Project Title: Pilot Study: Ambulatory Cognitive Assessments

Date: December 21, 2021 at 5:28 pm

Request ID: S1610

Aim 1: Determine the feasibility and utility of ambulatory cognitive assessments using measurment burst design.

Aim 2:

Aim 3:

Aim 4:


Investigator: Ganesh Babulal

Project Title: Racial differences in Alzheimer�s disease biomarkers and driving behavior

Date: December 21, 2021 at 5:28 pm

Request ID: S1609

Aim 1: We will determine, in a sample of 60 older adults, aged 65 years and older, with normal baseline cognition (Clinical Dementia Rating of 0), whether there are differences in values of cerebrospinal fluid (CSF) biomarkers and imaging amyloid uptake between African Americans and Caucasians

Aim 2: In the same sample, we will examine whether there are differences in African Americans and Caucasians cross-sectionally and longitudinally in daily driving behavior using an in-vehicle recording device and on a road test

Aim 3:

Aim 4:


Investigator: B, Joy Snider (WU site)

Project Title: Protocol 221AD301 A phase 3 Multicenter, RCT to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer�s Disease (ENGAGE Study)

Date: December 21, 2021 at 5:28 pm

Request ID: S1607

Aim 1: Evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the CDR-SB score as compared with placebo in subjects with early AD.

Aim 2: Evaluate the efficacy of aducanumab on MMSE, ADAS-Cog13, ADCS-ADL

Aim 3:

Aim 4:


Investigator: Beau M. Ances, MD, PhD

Project Title: Allzheimer Disease Neuroimaging Initiative 3 (ADNI3)

Date: December 21, 2021 at 5:28 pm

Request ID: S1606

Aim 1: To discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research

Aim 2: To capture rates of decline on cognitive, global and functional tests and the rate of conversion to MCI or dementia due to AD.

Aim 3: Determine the longitudinal extent and rate of amyloid and tau deposition in PET Scans and longitudinal change of cerebral tau correlated and compared with other changes in cognition and biomarkers

Aim 4: Determine which clinical, cognitive and biomarker and imaging capture detection of treatment effects and measure cognitive decline for all groups with a focus on biomarkers and Tau.


Investigator: John C. Morris, MD

Project Title: Protocol 54861911ALZ2003: Investigating the Efficacy and Safety of JNJ-54861911 in Subjects who are Asymptomatic At Risk for Developing Alzheimer’s Dementia

Date: December 21, 2021 at 5:28 pm

Request ID: S1605

Aim 1: To deteremine whether treatment with JNJ-54861911 slows cognitive decline compared with placebo treatement, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive Composite, in amyloid positive subjects who are asymptomatic at risk for developing Alzheimer’s dementia.

Aim 2: To assess the overall safety and tolerability of JNJ-54861911 versus placebo.

Aim 3: To assess the effect of JNJ-54861911 compared with placebo on the Clinical Dementia Rating (CDR) scale, including progression from CDR 0 to CDR 0.5 or higher

Aim 4: To assess the maintenance of JNJ-54861911 effects on markers of AB processing in CSF and plasma compared with placebo.


Investigator: Gregory Van Stavern, MD

Project Title: Ocular biomarkers in early and pre-clinical AD

Date: December 21, 2021 at 5:28 pm

Request ID: S1508

Aim 1: Assess differences in OCT metrics between normals, pre-clinical AD and early AD subjects

Aim 2: Assess changes in retinal and optic nerve blood flow in pre-clinical and early AD

Aim 3: Measure subretinal protein degradation products using OCT and compare with brain ABeta

Aim 4:


Investigator: John C. Morris, MD

Project Title: Lilly LY3202626 (BACE Inhibitor) NAVIGATE-AD Trial

Date: December 21, 2021 at 5:28 pm

Request ID: S1604

Aim 1: Safety/tolerability of LY3202626

Aim 2:

Aim 3:

Aim 4: